Entinostat: a promising treatment option for patients with advanced breast cancer.

Item

http://www.wikidata.org/entity/Q38741783

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Entinostat: a promising treatment option for patients with advanced breast cancer.

@en

type

Item

label

Entinostat: a promising treatment option for patients with advanced breast cancer.

@en

prefLabel

Entinostat: a promising treatment option for patients with advanced breast cancer.

@en

P1476

Entinostat: a promising treatment option for patients with advanced breast cancer.

@en

P2093

Michelle A Rudek

http://www.w3.org/2001/XMLSchema#string

Richard Piekarz

http://www.w3.org/2001/XMLSchema#string

Roisin M Connolly

http://www.w3.org/2001/XMLSchema#string

P2860

A decade of exploring the cancer epigenome - biological and translational implications

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

The fundamental role of epigenetic events in cancer

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy.

A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression

Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography.

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

P304

1137-1148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0526

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28326839

http://www.w3.org/2001/XMLSchema#string

P932

5618943

http://www.w3.org/2001/XMLSchema#string